Free shipping on all orders over $ 500

BTK Bruton Tyrosine Kinase

Cat.No.  Name Information
M1825 PCI-32765 PCI-32765 (Ibrutinib) is a potent, selective and orally bioavailable irreversible inhibitor of BTK with IC50 value of 0.46 nM.
M43813 NX-2127 NX-2127 is an orally active, potent BTK inhibitor that induces degradation of mutant BTKC481S in cells, as well as inhibits the proliferation of BTKC481S mutant TMD8 cells. In addition, NX-2127 stimulates T cell activation and increases IL-2 production in primary human T cells.
M14880 BMX-IN-1 BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys496 in the BMX ATP binding domain with an IC50 of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity.
M14879 (±)-Zanubrutinib (±)-Zanubrutinib ((±)-BGB-3111) is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor.
M10605 Rilzabrutinib Rilzabrutinib, also known as PRN1008, is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK) with IC50 of 1.3 nM.
M10604 Pirtobrutinib (LOXO-305) Pirtobrutinib (LOXO-305; LY 3527727; RXC-005) is a first-in-class, highly selective, non-covalent, next-generation BTK inhibitor with an IC50 of 5.69 nM in WT BTK HEK cells.Pirtobrutinib's selectivity for BTK more than 300 times more selective than other 370 kinases. Pirtobrutinib can be used in studies related to chronic lymphocytic leukemia (CLL).
M10500 Remibrutinib (LOU064) Remibrutinib (LOU064) is a potentially best-in-class "best-in-class" orally active bruton tyrosine kinase (BTK) inhibitor with an IC50 value of 1 nM and an IC50 value of 0.23 μM for inhibition of BTK activity in blood. Remibrutinib can be used to study chronic urticaria (CU).
M10274 Tolebrutinib Tolebrutinib (SAR442168) is a potent, selective, orally active and blood-brain barrier capable bruton's tyrosine kinase (BTK) inhibitor with IC50 values of 0.4 and 0.7 nM in Ramos B cells and HMC microglia, respectively. Tolebrutinib has an effect on central nervous system immunity. Tolebrutinib can be used in multiple sclerosis (MS) studies.
M10095 Orelabrutinib Orelabrutinib is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).
M10025 Zanubrutinib Zanubrutinib (BGB-3111) is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK).
M9958 ARQ 531 ARQ 531 is a potent reversible inhibitor of BTK (IC50 = 0.85 nM), exhibits potent antitumor activity in ibrutinib-resistant diffuse large B-cell lymphoma.
M9889 PCI-29732 PCI-29732 is a potent, reversible BTK inhibitor with Kiapp values of 8.2, 4.6, and 2.5 nM for BTK, Lck, and Lyn, respectively, and has only modest inhibitory activity against Itk, another Tec family kinase. In addition, PCI 29732 inhibits the function of ABCG2 by competitively binding to the ATP binding site of ABCG2.
M9628 Branebrutinib Branebrutinib (BMS-986195) is a potent, covalent, irreversible inhibitor of Bruton’s tyrosine kinase (BTK), with IC50 of 0.1 nM.
M9166 BMS-986142 BMS-986142 is a potent, selective, reversible BTK inhibitor, shows BTK IC50 = 0.5nM; human WB IC50 = 90 nM.
M8941 GDC-0853 (Fenebrutinib) GDC-0853 (Fenebrutinib) is a potent, selective and non-covalent bruton tyrosine kinase (Btk) inhibitor with a Ki value of 0.91 nM against BRK.
M8887 Btk inhibitor 2 Btk inhibitor 2 (BGB-3111) is a Brutons tyrosine kinase (BTK) inhibitor.
M7536 BMS-935177 BMS-935177 is a potent, reversible Bruton's Tyrosine Kinase (BTK) inhibitor with an IC50 value of 2.8 nM and demonstrates good kinase selectivity. It is more potent against BTK than other kinase, including the other Tec family kinases (TEC, BMX, ITK, and TXK) over which the compound is between 5- and 67-fold selective.
M6907 (Z)-LFM-A13 LFM-A13 is a specific Bruton's tyrosine kinase (BTK) inhibitor with IC50 of 2.5 μM.
M6636 CTA 056 CTA 056 is a iTK inhibitor.
M5333 Tirabrutinib (ONO-4059) Tirabrutinib (ONO-4059) is a highly selective, orally bioavailable BTK inhibitor with a potency (IC50) of 2.2 nM.




Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.